Cardiovascular Risk Management in Clinical Practice

Cardiovascular disease (CVD) still represents the leading cause of morbidity and mortality in Western countries and is expected to rise further, worldwide, in the future. The enormous impact of CVD on global health necessitates an inquiry into improvement of the existing approach to treatment. The common observation that CVD risk factors often occur in clusters may indeed represent a clinical opportunity because of the fact that the presence of a single risk factor indicates the likelihood that others are present. Clustering of multiple risk factors increases the severity of CVD risk, beyond that implied by simply adding the risk factors together. Physicians understand the multifactorial nature of CVD; in practice, they tend to treat risk factors in isolation, rather than addressing the global CVD risk continuum. A more comprehensive and effective approach to the multifactorial nature of CVD is needed. Managing the CVD risk continuum is a new treatment paradigm that can be moved forward. Tools are available to support this new model. Implementing this paradigm will help to target overall CVD risk while maintaining specific therapeutic goals for individual risk factors. This synergistic approach holds the best promise for treating total CVD risk, and reducing the mounting burden of CVD.

[1]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[2]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[3]  J. Buckroyd,et al.  Experience of service provision for adolescents with eating disorders , 2004, Primary Health Care Research & Development.

[4]  M. Elisaf.  The Treatment of Coronary Heart Disease: An Update , 2001, Current medical research and opinion.

[5]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[6]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[7]  W. Kannel,et al.  Risk stratification in hypertension: new insights from the Framingham Study. , 2000, American journal of hypertension.

[8]  Taghreed Adam,et al.  The burden and costs of chronic diseases in low-income and middle-income countries , 2007, The Lancet.

[9]  J. Bring,et al.  Bmc Family Practice the Role of Guidelines and the Patient's Life-style in Gps' Management of Hypercholesterolaemia , 2004 .

[10]  R. Sega,et al.  [The global cardiovascular risk chart]. , 2004, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[11]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[12]  Anthony Rodgers,et al.  Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk , 2003, The Lancet.

[13]  B. Williams,et al.  Managing cardiovascular risk: the need for change , 2008, Journal of Human Hypertension.

[14]  N. Tajima,et al.  RETRACTED: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study , 2007, The Lancet.

[15]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[16]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[17]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[18]  G. De Backer,et al.  Blood pressure is insufficiently controlled in European patients with established coronary heart disease , 2003, Journal of hypertension.

[19]  R B D'Agostino,et al.  Primary and subsequent coronary risk appraisal: new results from the Framingham study. , 2000, American heart journal.

[20]  B. Neal.  The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .

[21]  C. Murray,et al.  Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment , 2006, The Lancet.

[22]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[23]  G. Mancia,et al.  Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study , 2005, Journal of hypertension.

[24]  P. Whincup,et al.  Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. , 2004, European heart journal.

[25]  Michael Pignone,et al.  Framingham-based tools to calculate the global risk of coronary heart disease , 2003, Journal of general internal medicine.

[26]  Colin Baigent,et al.  Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.

[27]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[28]  The Treatment of Coronary Heart Disease: An Update , 2001, Current medical research and opinion.

[29]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[30]  Helmut Schulte,et al.  Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks. , 2002, International journal of epidemiology.

[31]  J F Potter,et al.  Extract from : , 2009 .

[32]  G. Mancia,et al.  Metabolic Syndrome , 2015 .

[33]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[34]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[35]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[36]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[37]  H Tunstall-Pedoe,et al.  The Dundee coronary risk-disk for management of change in risk factors. , 1991, BMJ.

[38]  J. Laragh,et al.  Hypertension guidelines: criteria that might make them more clinically useful. , 2002, American journal of hypertension.

[39]  Lisa B. Mirel,et al.  Blood Lead Levels and Death from All Causes, Cardiovascular Disease, and Cancer: Results from the NHANES III Mortality Study , 2006, Environmental health perspectives.

[40]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[41]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[42]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[43]  M. Abrahamowicz,et al.  Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study , 1995, BMJ.

[44]  A. Laupacis,et al.  Revisiting Rose: strategies for reducing coronary heart disease , 2006, BMJ : British Medical Journal.

[45]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[46]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[47]  J. Cox,et al.  Evidence-based cardiovascular care. Family physicians' views of obstacles and opportunities. , 2004, Canadian family physician Medecin de famille canadien.

[48]  Ralph B D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[49]  L. Erhardt,et al.  Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. , 2002, Family practice.

[50]  J. Bensing,et al.  Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine. , 2000, Patient education and counseling.

[51]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[52]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[53]  J. Laragh,et al.  Beyond hypertension: Toward guidelines for cardiovascular risk reduction , 2004 .

[54]  J. Neaton,et al.  Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. , 1992, Archives of internal medicine.

[55]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[56]  J. Bring,et al.  How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? , 2004, Primary Health Care Research & Development.

[57]  A. Hoes,et al.  Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk , 2005, Heart.

[58]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[59]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[60]  James D. Neaton,et al.  Serum Cholesterol, Blood Pressure, Cigarette Smoking, and Death From Coronary Heart Disease Overall Findings and Differences by Age for 316099 White Men , 1992 .

[61]  M. Volpe,et al.  Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician survey , 2004, Current medical research and opinion.

[62]  M. Barbagallo,et al.  Ageing, lifestyle modifications, and cardiovascular disease in developing countries. , 2006, The journal of nutrition, health & aging.

[63]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[64]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[65]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[66]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[67]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[68]  M. Woodward,et al.  Joint Effects of Systolic Blood Pressure and Serum Cholesterol on Cardiovascular Disease in the Asia Pacific Region , 2005, Circulation.